SSY vs. NEXI, LGVN, CHRO, PRTG, POAI, KTRA, XCUR, SNPX, CPHI, and ALZN
Should you be buying SunLink Health Systems stock or one of its competitors? The main competitors of SunLink Health Systems include NexImmune (NEXI), Longeveron (LGVN), Chromocell Therapeutics (CHRO), Portage Biotech (PRTG), Predictive Oncology (POAI), Kintara Therapeutics (KTRA), Exicure (XCUR), Synaptogenix (SNPX), China Pharma (CPHI), and Alzamend Neuro (ALZN). These companies are all part of the "medical" sector.
NexImmune (NASDAQ:NEXI) and SunLink Health Systems (NYSE:SSY) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation.
9.9% of NexImmune shares are held by institutional investors. Comparatively, 23.7% of SunLink Health Systems shares are held by institutional investors. 19.4% of NexImmune shares are held by insiders. Comparatively, 26.5% of SunLink Health Systems shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
In the previous week, NexImmune and NexImmune both had 1 articles in the media. SunLink Health Systems' average media sentiment score of 1.00 beat NexImmune's score of 0.00 indicating that NexImmune is being referred to more favorably in the media.
SunLink Health Systems has higher revenue and earnings than NexImmune. SunLink Health Systems is trading at a lower price-to-earnings ratio than NexImmune, indicating that it is currently the more affordable of the two stocks.
NexImmune has a beta of 1.85, indicating that its stock price is 85% more volatile than the S&P 500. Comparatively, SunLink Health Systems has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.
NexImmune has a net margin of 0.00% compared to NexImmune's net margin of -16.69%. NexImmune's return on equity of -18.36% beat SunLink Health Systems' return on equity.
NexImmune received 22 more outperform votes than SunLink Health Systems when rated by MarketBeat users. Likewise, 61.11% of users gave NexImmune an outperform vote while only 0.00% of users gave SunLink Health Systems an outperform vote.
Summary
SunLink Health Systems beats NexImmune on 7 of the 13 factors compared between the two stocks.
Get SunLink Health Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for SSY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SSY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
SunLink Health Systems Competitors List
Related Companies and Tools
